11 Einträge gefunden

1. Pancytopenia of unknown origin in a 52-year-old patient, Unklare Panzytopenie bei einem 52-jährigen Patienten

   1. Heidenreich, S
   2. van Randenbourgh, A
   3. Ayuk, F
   4. Kröger, N
   5. Schmiedel, S
   6. Asemissen, A
   7. Oelrich, Jennyfer

   2019 - Forschungsinformationssystem des UKE
2. Impact of molecular residual disease post allografting in myelofibrosis patients

   1. Wolschke, C
   2. Badbaran, A
   3. Zabelina, T
   4. Christopeit, M
   5. Ayuketang, Francis Ayuk
   6. Triviai, I
   7. Zander, A

   2017 - Forschungsinformationssystem des UKE
3. Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis

   1. Christopeit, M
   2. Badbaran, A
   3. Zabelina, T
   4. Zeck, G
   5. Fehse, B
   6. Ayuketang, Francis Ayuk
   7. Wolschke, C

   2016 - Forschungsinformationssystem des UKE
4. Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation

   1. Badbaran, A
   2. Fehse, B
   3. Christopeit, M
   4. Aranyossy, T
   5. Ayuketang, Francis Ayuk
   6. Wolschke, C
   7. Kröger, Nicolaus

   2016 - Forschungsinformationssystem des UKE
5. Suspected encephalitis with Candida tropicalis and Fusarium detected by unbiased RNA sequencing

   1. Christopeit, M
   2. Grundhoff, A
   3. Rohde, H
   4. Belmar-Campos, C
   5. Grzyska, U
   6. Fiehler, J
   7. Wolschke, C

   2016 - Forschungsinformationssystem des UKE
6. Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)

   1. Kröger, Nicolaus
   2. Bornhäuser, M
   3. Stelljes, M
   4. Pichlmeier, U
   5. Trenschel, R
   6. Schmid, C
   7. Arnold, R

   2015 - Forschungsinformationssystem des UKE
7. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis

   1. Stübig, T
   2. Alchalby, H
   3. Ditschkowski, M
   4. Wolf, D
   5. Wulf, G
   6. Zabelina, T
   7. Wolschke, C

   2014 - Forschungsinformationssystem des UKE
8. Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation

   1. Wolschke, C
   2. Zabelina, T
   3. Ayuketang, Francis Ayuk
   4. Alchalby, H
   5. Berger, Juergen
   6. Klyuchnikov, E
   7. Pein, U-M

   2014 - Forschungsinformationssystem des UKE
9. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.

   1. Kröger, N
   2. Zabelina, T
   3. Klyuchnikov, E
   4. Kropff, M
   5. Pflüger, K-H
   6. Burchert, A
   7. Stübig, T

   2013 - Forschungsinformationssystem des UKE
10. Donor choice according to age for allo-SCT for AML in complete remission

    1. Ayuketang, Francis Ayuk
    2. Zabelina, T
    3. Wortmann, F
    4. Alchalby, H
    5. Wolschke, C
    6. Lellek, H
    7. Bacher, U

    2013 - Forschungsinformationssystem des UKE
11. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

    1. Schroeder, T
    2. Czibere, A
    3. Platzbecker, U
    4. Bug, G
    5. Uharek, L
    6. Luft, T
    7. Giagounidis, A

    2013 - Forschungsinformationssystem des UKE